Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

2021 Conferences

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a
Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.